IDEXX Cancer Dx testing
A revolutionary new cancer panel for dogs that detects lymphoma earlier than ever.1
Coming in late March 2025.
Find cancer early.
So you can fight it early.
- Detect and specifically identify lymphoma with a simple blood specimen.1
- Can be affordably and easily incorporated into testing for sick pets and IDEXX Preventive Care profiles for at-risk dogs.†
- Actionable next-step guidance from world-class oncologists.
- According to early data, IDEXX Cancer Dx testing can detect lymphoma before clinical signs are present.1
A new recruit in the war against cancer.
Cancer is a leading cause of death in canines, with 1 in 4 dogs in the U.S. expected to be diagnosed with cancer in their lifetime.2 73% of pet owners are interested in having a cancer screening test for their pet—and now you can offer them one.3
IDEXX Cancer Dx testing is built from a panel of revolutionary biomarkers that test for lymphoma through multimodal bioanalytical techniques, accurately detecting lymphoma in at-risk dogs.†1
Early. Accurate. The first of its kind.
IDEXX Cancer Dx testing has 74% sensitivity, and 99% specificity rates.1
B-cell versus T-cell phenotype classification will be provided with positive results as available at no additional cost.
Detecting lymphoma earlier is just the beginning.
IDEXX Cancer Dx testing is launching in late March 2025, starting with lymphoma detection. But that’s just the beginning. In the coming years, we plan to add detection of more of the most common canine cancers. IDEXX Cancer Dx testing fits seamlessly into your IDEXX preventive care screening and sick patient testing protocols.
We added deeper insights to your preventive care offering.
Cancer screening is an important part of preventive care diagnostics for at-risk dogs.† IDEXX Preventive Care helps veterinarians tailor recommendations for every patient’s needs. It’s a comprehensive solution that includes a team of experts to help implement best practices and powerful tools to spot trends and interpret patient results, now including IDEXX Cancer Dx testing.
Before you can fight cancer, you have to find it.
We recommend screening at-risk dogs, including all dogs aged 7 or older and dogs of high-risk breeds aged 4 or older, particularly in the following breeds:
| Labrador retriever French bulldog Golden retriever German shepherd Beagle Rottweiler Boxer Pembroke Welsh corgi |
Great Dane Miniature schnauzer Siberian husky Bernese mountain dog Mastiff Irish wolfhound Flat-coated retriever Scottish wolfhound |
Put our cancer portfolio to work.
We've developed a full suite of diagnostic tools for treatment, monitoring, management, and support for every stage of veterinary oncology.
Support
Resources
Access IDEXX Cancer Dx testing resources, including diagnostic updates, white papers, guides, blog articles, links to webinars and courses, and more.
Tests and services
See the advanced menu of tests offered by IDEXX Reference Laboratories.
Medical consultants
Direct live access and personalized guidance from our team of IDEXX experts, including our Diagnostic Support Technicians, Diagnostic Support Veterinarians, and board-certified veterinary specialists.
†At-risk dogs include all dogs ≥ 7 years old and high-risk breeds ≥ 4 years old.
References
- Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Data based on testing performed at IDEXX Reference Laboratories in North America between November 1, 2024, and December 6, 2024. Analysis Report: IDEXX Cancer Dx Validation, 100282 [008_CancerDx-Validation-Report-2.Rmd].
- What are the most common types of cancers in dogs? How many dogs typically get cancer? Veterinary Cancer Society; 2021. Accessed January 13, 2025. www.vetcancersociety.org/pet-owners/faqs
- Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: IDEXX quantitative research with dog owners, May 2024 (n = 480).